You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Acorda Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Acorda
International Patents:91
US Patents:6
Tradenames:2
Ingredients:2
NDAs:2
PTAB Cases with Acorda as patent owner: See PTAB cases with Acorda as patent owner

Drugs and US Patents for Acorda

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes 8,685,442 ⤷  Try a Trial Y ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes RE43711 ⤷  Try a Trial ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes 8,545,878 ⤷  Try a Trial Y ⤷  Try a Trial
Acorda AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250-001 Jan 22, 2010 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes 8,945,612 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Acorda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 7,384,649 ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 6,514,482 ⤷  Try a Trial
Acorda AMPYRA dalfampridine TABLET, EXTENDED RELEASE;ORAL 022250-001 Jan 22, 2010 5,540,938 ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 6,979,437 ⤷  Try a Trial
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 7,146,978 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ACORDA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 10 mg ➤ Subscribe 2014-01-22

Supplementary Protection Certificates for Acorda Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1613296 CR 2015 00042 Denmark ⤷  Try a Trial PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
1613296 92782 Luxembourg ⤷  Try a Trial PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.